Clinical Trials · global
Silencing a Coagulation Signal in the Liver: Argo’s Factor XI siRNA Enters Human Trials for the First Time
BW-41012 has begun a Phase I dose-escalation study in Australia, initially assessing safety, pharmacokinetics, and whether it can sustainably reduce Factor XI in healthy adults; its clinical benefit in preventing thrombosis and its bleeding risk remain to be answered by subsequent trials.
Thrombosis treatment has long faced a dilemma: reducing coagulation can prevent events such as stroke and deep vein thrombosis, but it may also increase the risk of bleeding. Argo Biopharma announced that the first participant has been dosed in an Australian Phase I trial of BW-41012, a small interfering RNA drug candidate targeting coagulation Factor XI, bringing this anticoagulation strategy—which still awaits clinical validation—into human testing.
BW-41012 is administered by subcutaneous injection and is designed to silence Factor XI messenger RNA, reducing production of the associated protein at its source. Factor XI participates in the amplification of the coagulation response. The developer hopes that inhibiting this step can reduce thrombus formation while preserving more of the body’s everyday hemostatic capacity. However, there are currently no human results available to determine whether this theoretical safety window applies to BW-41012.
The study, registered as NCT07584876, uses a randomized, double-blind, placebo-controlled, single-ascending-dose design and is expected to enroll approximately 40 healthy adults in Perth, Western Australia, divided into five cohorts of eight participants each. The trial will first record adverse events, serious adverse events, and changes in laboratory values, while tracking changes in the drug’s concentration in the body over time.
The study will also measure Factor XI activity and antigen concentration, as well as activated partial thromboplastin time (aPTT). These measures can help confirm whether the drug engages its intended target and determine the strength and duration of its effect, but they cannot directly prove that it can prevent thrombotic events in patients. Because the participants are healthy adults, this stage also cannot answer questions about efficacy, appropriate dosing, or long-term bleeding risk across different populations with thrombotic diseases.
ClinicalTrials.gov lists the study start date as May 29, 2026. As of the July 9 update, its status was recruiting, with primary study completion estimated for October 2027 and the overall trial continuing through January 2028. This timeline means that dosing the first participant is only the starting point of clinical development, and a complete safety and pharmacodynamic profile will require waiting for each dose cohort to be completed in turn.
Argo also stated that BW-41012 received clinical trial authorization from China’s National Medical Products Administration in July 2026, with subsequent plans covering broader global development. The company identifies it as the eighth candidate in its RNA interference pipeline to enter clinical development. However, this milestone primarily demonstrates that the program has advanced into human testing; it does not mean that regulators have confirmed its efficacy, nor are there sufficient patient data to compare it with existing anticoagulant therapies.